Seminars in Hematology
Volume 43 , Pages S8-S13 , April 2006

Current Opinion on Inhibitor Treatment Options

  • Prasad Mathew

      Affiliations

    • Corresponding Author InformationAddress correspondence to Prasad Mathew, MD, University of New Mexico, Department of Pediatrics, MSC 10 5590, 1 University of New Mexico, Albuquerque, NM, 87113.

References 

  1. Kasper CK . Diagnosis and Management of Inhibitors to Factors VIII and IX. An Introductory Discussion for Physicians. Treatment of Hemophilia Monograph Series, No. 34 . Montreal, Québec, Canada: World Federation of Hemophilia; 2004;
  2. DiMichele D . Inhibitors (Resolving diagnostic and therapeutic dilemmas) . Haemophilia . 2002;8:280–287
  3. Wight J , Paisley S . The epidemiology of inhibitors in haemophilia A (A systemic review) . Haemophilia . 2003;9:418–435
  4. Kessler CM . New perspectives in hemophilia treatment . Hematology . 2005;429–435 Am Soc Hematol Educ Program
  5. Kasper CK , Aledort L , Aronson D , Counts R , Edson JR , van Eys J , et al.   Proceedings (A more uniform measurement of factor VIII inhibitors) . Thromb Diath Haemorrh . 1975;34:612
  6. White GC , Rosendaal F , Aledort LM , Lusher JM , Rothschild C , Ingerslev J  Factor VII and Factor IX Subcommittee . Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis . Thromb Haemost . 2001;85:560
  7. Rothschild C , Gill J , Scharrer I , Bray G . Transient inhibitors in the Recombinate PUP study . Thromb Haemost . 2000;84:145–146
  8. DiMichele D , Rivard G , Hay C , Antunes S . Inhibitors in haemophilia (Clinical aspects) . Haemophilia . 2004;10(suppl 4):140–145
  9. Lessinger CA . Prevention of bleeds in hemophilia patients with inhibitors (Emerging data and clinical direction) . Am J Hematol . 2004;77:187–193
  10. Gringeri A , Mantovani LG , Scalone L , Mannucci PM  COCIS Study Group . Cost of care and quality of life for patients with hemophilia complicated by inhibitors (The COCIS Study Group) . Blood . 2003;102:2358–2363
  11. Darby SC , Keeling DM , Spooner RJ , Wan Kan S , Giangrande PL , Collins PW , et al.   The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99 . J Thromb Haemost . 2004;2:1047–1054
  12. Rodriguez-Merchan EC , Rocino A . Literature review of surgery management in inhibitor patients . Haemophilia . 2004;10(suppl 2):22–29
  13. Ananyeva NM , Lacroix-Desmazes S , Hauser CA , Shima M , Ovanesov MV , Khrenov AV , et al.   Inhibitors in hemophilia A (Mechanisms of inhibition, management and perspectives) . Blood Coagul Fibrinolysis . 2004;15:109–124
  14. Lusher JM , Blatt PM , Penner JA , Aledort LM , Levine PH , White GC , et al.   Autoplex versus proplex (A controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII) . Blood . 1983;62:1135–1138
  15. Négrier C , Goudemand J , Sultan Y , Bertrand M , Rothschild C , Lauroua P  French FEIBA Study Group . Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors . Thromb Haemost . 1997;77:1113–1119 Factor Eight Bypassing Activity
  16. Négrier C  French FEIBA Study Group . FEIBA VH in home treatment—A 3-year prospective experience . In: Haemophilia . 4: 1998;p. 238; Presented at the XXIII International Congress of the World Federation of Hemophilia in The Hague, The Netherlands. (abstr 33)
  17. Kreuz W , Ettingshausen CE , Mentzer D , Martinez Saguer I , Becker S , Stoll H , et al.   Immune tolerance induction (ITI) and factor VIII inhibitor bypass activity (FEIBA) for prophylaxis in patients with high responding inhibitors . Ann Hematol . 2001;80(suppl 1):A38; (abstr 138)
  18. Kreuz W , Ettingshausen CE , Martinez I , Mentzer D , Figura S , Klarmann  . Efficacy and safety of factor VIII inhibitor bypass activity (Feiba) for long-term prophylaxis in patients with high-responding inhibitors . Blood . 2000;96:265a; (abstr 1140)
  19. Young G , McDaniel M , Nugent DJ . Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors . Haemophilia . 2005;11:203–207
  20. Saxon BR , Shanks D , Jory CB , Williams V . Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-Novoseven) in a child with high titre inhibitors and a target joint . Thromb Haemost . 2001;86:1126–1127
  21. Bryant PC , Carr ME , Martin EJ , Sutton JF . High dose recombinant activated factor VII in a pediatric patient with factor VIII deficiency and high titer inhibitor . Blood . 2003;102:104b; (abstr 4128)
  22. Kreuz W , Ettingshausen CE , Auerswald G , Saguer IM , Becker S , Funk M , et al.   Epidemiology of inhibitors and current treatment strategies . Haematologica . 2003;88:17–20
  23. Hay CRM , Baglin TP , Collins PW , Hill FGH , Keeling DM . The diagnosis and management of factor VIII and IX inhibitors (A guideline from the UK Haemophilia Centre Doctors’ Organization (UKHCDO)) . Br J Haematol . 2000;111:78–90
  24. Uehlinger J , Button GR , McCarthy J , Forster A , Watt R , Aledort LM . Immunoadsorption for coagulation factor inhibitors . Transfusion . 1991;31:265–269
  25. Teitel JM . Recombinant factor VIIa versus aPCCs in haemophiliacs with inhibitors (Treatment and cost considerations) . Haemophilia . 1999;5(suppl 3):43–49
  26. Hilgartner MW , Knatterud GL . The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors . Blood . 1983;61:36–40
  27. Hilgartner M , Aledort L , Andes A , Gill J  FEIBA Study Group . Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients . Transfusion . 1990;30:626–630
  28. Wilde JT . Evidence for the use of activated prothrombin complex concentrates (aPCCs) in the treatment of patients with haemophilia and inhibitors . Pathophysiol Haemost Thromb . 2002;32(suppl 1):9–12
  29. Luu H , Ewenstein B . FEIBA safety profile in multiple modes of clinical and home-therapy application . Haemophilia . 2004;10(suppl 2):10–16
  30. Ehrlich HJ , Henzl MJ , Gomperts ED . Safety of factor VIII inhibitor bypass activity (FEIBA) (10-year compilation of thrombotic adverse events) . Haemophilia . 2002;8:83–90
  31. Shapiro AD , Gilchrist GS , Hoots WK , Cooper HA , Gastineau DA . Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery . Thromb Haemost . 1998;80:773–778
  32. Key NS , Aledort LM , Beardsley D , Cooper HA , Davignon G , Ewenstein BM , et al.   Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors . Thromb Haemost . 1998;80:912–918
  33. Aledort LM . Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity . J Thromb Haemost . 2004;2:1700–1708
  34. Mariani G , Kroner B  Immune Tolerance Study Group (ITSG) . Immune tolerance in hemophilia with factor VIII inhibitors (Predictors of success) . Haematologica . 2001;86:1186–1193
  35. DiMichele DM , Kroner BL  North American Immune Tolerance Study Group . The North American Immune Tolerance Registry (Practices, outcomes, outcome predictors) . Thromb Haemost . 2002;87:52–57
  36. Auerswald G , Spranger T , Brackmann HH . The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients . Haematologica . 2003;88:21–25
  37. Gensana M , Altisent C , Aznar JA , Casaña P , Hernàndez F , Jorquera JI , et al.   Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII . Haemophilia . 2001;7:369–374
  38. Berntorp E . Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations (Is it of clinical importance?) . Haematologica . 2003;88:13–16
  39. Sakurai Y , Shima M , Tanaka I , Fukuda K , Yoshida K , Yoshioka A . Association of anti-idiotypic antibodies with immune tolerance induction for the treatment of hemophilia A with inhibitors . Haematologica . 2004;89:696–703
  40. Gilles JG , Vanzieleghem B , Saint-Remy J-MR . Natural autoantibodies and anti-idiotypes . Semin Thromb Hemost . 2000;26:151–155
  41. Gilles JG , Saint-Remy JM . Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies . J Clin Invest . 1994;94:1496–1505
  42. Terada K , Yagi Y , Niizuma T , Kataoka N . Is oral tolerance therapy possible for haemophilia with inhibitors? . Vox Sang . 2001;80:61–62
  43. Wiestner A , Cho HJ , Asch AS , Michelis MA , Zeller JA , Peerschke EIB , et al.   Rituximab in the treatment of acquired factor VIII inhibitors . Blood . 2002;100:3426–3428
  44. Barrow RT , Healey JF , Gailani D , Scandella D , Lollar P . Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules . Blood . 2000;95:564–568

 This article is based in part on the proceedings from an educational symposium held at the World Federation of Hemophilia World Congress 2004 in Bangkok, Thailand. Both the symposium and the manuscript were supported by Baxter Healthcare Corporation.

PII: S0037-1963(06)00051-5

doi: 10.1053/j.seminhematol.2006.03.005

Seminars in Hematology
Volume 43 , Pages S8-S13 , April 2006

Article Tools

* Image Usage & Resolution